PRAXIS RISES, VENU VIBES, AND J.B. HUNT DELIVERS
DENVER, Colo., Oct 16, 2025 (247marketnews.com)- Praxis Precision Medicines (NASDAQ:PRAX) is making waves in biotech today, skyrocketing in early trading after announcing positive topline results from two pivotal Phase 3 studies of ulixacaltamide, its investigational treatment for essential tremor (ET).
- In Study 1, patients saw a 4.3-point improvement in mADL11 at Week 8 (p<0.0001), with all key secondary endpoints also meeting statistical significance.
- Study 2, a randomized withdrawal design, showed 55% of ulixacaltamide-treated patients maintained response, compared to 33% on placebo (p=0.0369).
- No drug-related serious adverse events were reported.
Praxis has submitted a pre-NDA meeting request with the FDA, eyeing a 2026 NDA filing. With a strong safety profile and demand reflected in 200,000+ study volunteers, the data positions ulixacaltamide as a first-in-class CNS breakthrough.
CEO Marcio Souza called the results “a powerful reflection of the large unmet need” for patients who’ve lived with ET for decades.
Clinical leadership echoed the impact, with Dr. Salima Brillman calling it “a real opportunity to help people regain their independence.”
VENU (NYSE:VENU) is gaining investor applause after unveiling striking designs for its Sunset Amphitheaters in McKinney, TX and Broken Arrow, OK. The next-gen venues, featuring heated canopies and year-round programming, are redefining premium live entertainment infrastructure.
- $23M in Luxe FireSuite sales booked in just 60 days
- Analysts tag a $22.30 Cenorium Price Target
- Company culturally backed by Dierks Bentley and Rolling Stone Culture Council
With renderings capturing investor imagination, VENU is shifting perception from infrastructure stock to aspirational brand. The buzz is tangible — this is less about sound systems and more about experience monetization.
Sonder Holdings (NASDAQ:SOND) shares are climbing despite a revenue decline, buoyed by significant improvements in occupancy (86%) and adjusted EBITDA. The company’s aggressive Portfolio Optimization Program led to a 21% YoY drop in bookable nights, but margins are improving:
- RevPAR: $184 (+13% YoY)
- Adjusted EBITDA: ($2.6M), +83% YoY
- Net Loss: $44.5M, down from $149M in Q2 ’24
With $71M in cash on hand and stronger unit economics, the company is fighting for sustainability in a tough hospitality landscape.
Tempus AI (NASDAQ:TEM) & Whitehawk Therapeutics (NASDAQ:WHWK) announced a multi-year collaboration to harness real-world data for cancer treatment optimization.
- Focused on ADC (antibody-drug conjugate) targets like PTK7, MUC16, SEZ6
- RNA expression to be used as scalable biomarker strategy
- Whitehawk aims to optimize trial design and target validation
This partnership leans into Tempus’ strength in multimodal datasets and Whitehawk’s growing oncology pipeline. Analysts are watching WHWK closely as this agreement could meaningfully advance its clinical programs in lung and gynecological cancers.
Plug Power (NASDAQ:PLUG) CEO Andy Marsh joins U.S. Sen. Bill Cassidy at today’s Louisiana Energy Security Summit to promote hydrogen’s role in energy independence.
Key takeaways:
- Discussing U.S. vs. China energy security
- Touting recent Hidrogenii JV with Olin Corporation
- Advocating “Foreign Pollution Fee Act” to level global playing fields
With Louisiana marked as a hydrogen hub and bipartisan interest growing in clean energy supply chains, Plug is reinforcing its role in shaping policy and infrastructure.
Aqua Metals (NASDAQ:AQMS) secured $13 million in funding via a registered direct offering to accelerate commercialization of its AquaRefining tech.
- Offering priced at $11.34/share, including prefunded warrants
- Warrants have 5-year exercisability
- Proceeds to be used for working capital and growth
The raise signals continued institutional confidence in AQMS’ closed-loop, clean lithium recycling model as EV and battery demands continue to climb.
J.B. Hunt Transport Services (NASDAQ:JBHT) reported Q3 earnings above expectations, highlighting operational discipline:
- EPS: $1.76 vs. $1.49 YoY (+18%)
- Revenue: $3.05B (flat)
- Operating Income: $242.7M (+8%)
Segment strength:
- Intermodal (JBI): Income +12% on network balance improvements
- Dedicated Services (DCS): Revenue +2%, Income +9%
- Truckload (JBT): Revenue +10%, Income down 9% due to equipment and insurance expenses
CEO Shelley Simpson praised cost discipline and network optimization. With ~$52M cash on hand and $230M in buybacks during the quarter, the company is leaning into shareholder returns amid stable fundamentals.
Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.
For the full 24/7 Market News VENU report and in-depth insights, including analyst reports, visit: Read 24/7 Market News VENU Report/
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: 247MarketNews.com has been compensated $2,500 per week by MicroCap Strategies for ongoing press and editorial coverage of VENU. This is a paid editorial communication intended for informational purposes only. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. This press release may include technical analysis for informational purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
CONTACT:
24/7 Market News
Editor@247marketnews.com